GDF15 promotes EMT and metastasis in colorectal cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2829 views | HTML 4175 views | ?
Chen Li1,4,*, Jingyu Wang1,2,5,*, Jianlu Kong1,4, Jinlong Tang1,3, Yihua Wu1, Enping Xu1,4, Honghe Zhang1,4, Maode Lai1,4
1Department of Pathology, School of Medicine, Zhejiang University, Zhejiang, PR China
2Department of Pathology, the First Hospital of Jiaxing, Zhejiang, PR China
3Department of Pathology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, PR China
4Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang, PR China
5Key Constructing Discipline by Zhejiang Province and Jiaxing City, Zhejiang, PR China
*These authors have contributed equally to this work
Honghe Zhang, e-mail: [email protected]
Maode Lai, e-mail: [email protected]
Keywords: GDF15, EMT, metastasis, colorectal cancer
Received: July 21, 2015 Accepted: October 15, 2015 Published: October 22, 2015
Metastasis is the major cause of cancer deaths, and the epithelial–mesenchymal transition (EMT) has been considered to be a fundamental event in cancer metastasis. However, the role of growth differentiation factor 15 (GDF15) in colorectal cancer (CRC) metastasis and EMT remains poorly understood. Here, we showed that GDF15 promoted CRC cell metastasis both in vitro and in vivo. In addition, the EMT process was enhanced by GDF15 through binding to TGF-β receptor to activate Smad2 and Smad3 pathways. Clinical data showed GDF15 level in tumor tissues, and the serum was significantly increased, in which high GDF15 level correlated with a reduced overall survival in CRC. Thus, GDF15 may promote colorectal cancer metastasis through activating EMT. Promisingly, GDF15 could be considered as a novel prognostic marker for CRC in the clinic.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.